2068
Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.
 ( adverse event: increase ,  patients with thalassemia intermedia: Subject, hemoglobin (Hb F) levels: Effect, Hydroxyurea (HU) and sodium phenylbutyrate (SPB): Treatment, Hydroxyurea: Treatment.Drug, sodium phenylbutyrate: Treatment.Drug, thalassemia intermedia: Treatment.Disorder, Hydroxyurea: Combination.Drug, sodium phenylbutyrate: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: increase ,  patients with thalassemia intermedia: Subject, hemoglobin (Hb F) levels: Effect, Hydroxyurea (HU) and sodium phenylbutyrate (SPB): Treatment, Hydroxyurea: Treatment.Drug, sodium phenylbutyrate: Treatment.Drug, thalassemia intermedia: Treatment.Disorder, Hydroxyurea: Combination.Drug, sodium phenylbutyrate: Combination.Drug) 